Literature DB >> 27629506

Dyslipidaemia: PCSK9 inhibitor reduces need for lipoprotein apheresis in familial hypercholesterolaemia.

Gregory B Lim.   

Abstract

Entities:  

Year:  2016        PMID： 27629506     DOI： 10.1038/nrcardio.2016.148

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  1 in total

1.  Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial.

Authors:  Patrick M Moriarty; Klaus G Parhofer; Stephan P Babirak; Marc-Andre Cornier; P Barton Duell; Bernd Hohenstein; Josef Leebmann; Wolfgang Ramlow; Volker Schettler; Vinaya Simha; Elisabeth Steinhagen-Thiessen; Paul D Thompson; Anja Vogt; Berndt von Stritzky; Yunling Du; Garen Manvelian
Journal:  Eur Heart J       Date:  2016-08-29       Impact factor: 29.983
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.